Promising pCR Rates with Neoadjuvant Durvalumab Plus Platinum-based Chemotherapy Combined with ADC for Patients with Resectable NSCLC By Ogkologos - July 29, 2025 424 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the NeoCOAST-2 study Source RELATED ARTICLESMORE FROM AUTHOR A Short-Course Dose Escalation Strategy Could Improve Ability to Reach Target Dose of Adjuvant Abemaciclib in High-Risk Early-Stage HR-positive, HER2-negative Breast Cancer FDA Approves Ziftomenib for Relapsed or Refractory Acute Myeloid Leukaemia with a NPM1 Mutation NEPA Plus Dexamethasone Provide Superior Chemotherapy-Induced Nausea and Vomiting Prevention Compared with SoC Antiemetic Prophylaxis MOST POPULAR Immunotherapy Plus Chemotherapy Helps People With Advanced Nasopharyngeal Cancer: The ASCO... April 18, 2022 Drug Shows Promise in Slowing Progression of Smoldering Myeloma to Cancer June 7, 2019 FDA Approves Lutetium Lu 177 Dotatate for Paediatric Patients 12 Years... May 15, 2024 Drug Combination May Have Potential for Cancers with TP53 Mutations April 4, 2024 Load more HOT NEWS Implementation of Molecular Tumour Board Portal Developed Under the Umbrella of... Rare Disease Day: Raising Awareness for Rare Cancers 2020 round-up: Our biggest cancer stories of the year First-Line 177Lu-Dotatate Plus Octreotide LAR Significantly Extends PFS in Patients with...
